SCHEMBL3933265

SCHEMBL3933265

Cc1ccc(N)cc1C(=O)Nc1cnc(N)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.61
CYP2C9 P11712 3/20 0.61
BTK Q06187 9/20 0.48
JAK2 O60674 2/20 0.48
CSF1R P07333 1/20 0.48
PDGFRB P09619 1/20 0.48
FGFR1 P11362 1/20 0.48
EPHB4 P54760 1/20 0.48
PTK2 Q05397 1/20 0.48
MAPK14 Q16539 1/20 0.48
BLK P51451 2/20 0.47
TYK2 P29597 1/20 0.47
DHODH Q02127 1/20 0.45
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GRM4 Q14833 1/20 0.45
KIT P10721 1/20 0.44
CHRNA7 P36544 1/20 0.43
LCK P06239 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3934918 0.83 CYP2C9 (0.56) BRAFCYP2C9SMN1; SMN2
SCHEMBL2943817 0.82 BLK (0.58) BTKMAPK14BLKKITLCK
SCHEMBL5815535 0.79 BRAF (0.56) BRAFCYP2C9BTKJAK2CSF1R
SCHEMBL3932501 0.77 BRAF (1.00) BRAFCYP2C9BTKJAK2CSF1R
SCHEMBL2943457 0.77 LCK (0.54) BRAFBTKJAK2MAPK14BLK
SCHEMBL1367088 0.77 BLK (0.45) BTKBLKALDH1A1SMN1; SMN2KIT
SCHEMBL1367703 0.77 PIK3CA (0.60) BRAFBTKBLKKIT
SCHEMBL3943854 0.76 BRAF (0.55) BRAFBTKCSF1RBLKALDH1A1
SCHEMBL4019946 0.76 KIT (0.59) BRAFBTKCSF1RMAPK14BLK
SCHEMBL24869675 0.76 CYP2C9 (0.50) BRAFCYP2C9JAK2CSF1RPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831198-B1 PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS ASTRAZENECA AB (SE) 2009-04-08 EP disclosed
CN-101128454-A Pyridine carboxamide derivatives for use as anticancer agents ASTRAZENECA AB (SE) 2008-02-20 CN disclosed